Equibles does not estimate personal net worth.
Get an email with a short summary when Tg Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get TGTX alertsMike Weiss is recorded as CEO at Tg Therapeutics, Inc. (TGTX). Mike Weiss has spoken on 3 earnings calls and 2 other investor events across 1 company, most recently for Tg Therapeutics, Inc. on September 14, 2026. Tg Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Tg Therapeutics, Inc. includes Michael S. Weiss (CEO and Board Member), Sean A. Power (CFO), Daniel Hume (Board Member) and 7 others.
“So, you know, for relapsing MS, we estimate that there's approximately 40,000 new patients per year.”
“Proctor, thank you for that five-part question. We'll try to break that down. Adam, do you want to start us off with some thoughts on sub-Q, part D, pricing and contracting and potential uptake?”
“You know, MG is something we've been thinking about for quite some time. we were able to get a small cohort of 11 patients into the Phase I sub-Q study. So that was really a nice addition for us.”
“Thank you, Jenna, and good morning, everyone, and thank you for joining us on today's call. I'm pleased to share that we delivered another strong quarter with solid performance across all aspects of our business, highlighted by the continued momentum of our flagship product, Briandie.”
“2023 is off to an excellent start for us at TG, with the US approval and commercial launch of BRIUMVI, and we are excited to be able to offer patients the first and only anti-CD20 monoclonal antibody approved for relapsing forms of MS that can be administered in a one-hour infusion twice a year following the starting…”
Biotechnology · Healthcare
CEO
